AAAAAA

   
Results: 1-15 |
Results: 15
Population-based health monitoring via computer-assisted telephone interviews in Bavaria
Authors: Fischer, R Meyer, N Weitkunat, R Crispin, A Schotten, K Uberla, K
Citation: R. Fischer et al., Population-based health monitoring via computer-assisted telephone interviews in Bavaria, GESUNDHEITS, 63, 2001, pp. S123-S129
Generation of replication-defective helper-free vectors based on simian immunodeficiency virus
Authors: Kim, SS Kothari, N You, XJ Robinson, WE Schnell, T Uberla, K Fan, H
Citation: Ss. Kim et al., Generation of replication-defective helper-free vectors based on simian immunodeficiency virus, VIROLOGY, 282(1), 2001, pp. 154-167
Information processing in healthcare at the start of the third millennium:Potential and limitations
Authors: Haux, R Knaup, P Bauer, AW Herzog, W Reinhardt, E Uberla, K van Eimeren, W Wahlster, W
Citation: R. Haux et al., Information processing in healthcare at the start of the third millennium:Potential and limitations, METH INF M, 40(2), 2001, pp. 156-162
Transfer of primer binding site-mutated simian immunodeficiency virus vectors by genetically engineered artificial and hybrid tRNA-like primers
Authors: Hansen, AC Grunwald, T Lund, AH Schmitz, A Duch, M Uberla, K Pedersen, FS
Citation: Ac. Hansen et al., Transfer of primer binding site-mutated simian immunodeficiency virus vectors by genetically engineered artificial and hybrid tRNA-like primers, J VIROLOGY, 75(10), 2001, pp. 4922-4928
Phenotypic HIV-1 resistance correlates with treatment outcome of nelfinavir salvage therapy
Authors: Walter, H Schmidt, B Rascu, A Helm, M Moschik, B Paatz, C Kurowski, M Korn, K Uberla, K Harrer, T
Citation: H. Walter et al., Phenotypic HIV-1 resistance correlates with treatment outcome of nelfinavir salvage therapy, ANTIVIR TH, 5(4), 2000, pp. 249-256
Development of a self-inactivating, minimal lentivirus vector based on simian immunodeficiency virus
Authors: Schnell, T Foley, P Wirth, M Munch, J Uberla, K
Citation: T. Schnell et al., Development of a self-inactivating, minimal lentivirus vector based on simian immunodeficiency virus, HUM GENE TH, 11(3), 2000, pp. 439-447
Rev-independent expression of synthetic gag-pol genes of human immunodeficiency virus type 1 and simian immunodeficiency virus: Implications for the safety of lentiviral vectors
Authors: Wagner, R Graf, M Bieler, K Wolf, H Grunwald, T Foley, P Uberla, K
Citation: R. Wagner et al., Rev-independent expression of synthetic gag-pol genes of human immunodeficiency virus type 1 and simian immunodeficiency virus: Implications for the safety of lentiviral vectors, HUM GENE TH, 11(17), 2000, pp. 2403-2413
Simple algorithm derived from a geno-/phenotypic database to predict HIV-1protease inhibitor resistance
Authors: Schmidt, B Walter, H Moschik, B Paatz, C van Vaerenbergh, K Vandamme, AM Schmitt, M Harrer, T Uberla, K Korn, K
Citation: B. Schmidt et al., Simple algorithm derived from a geno-/phenotypic database to predict HIV-1protease inhibitor resistance, AIDS, 14(12), 2000, pp. 1731-1738
Low level of cross-resistance to amprenavir (141W94) in samples from patients pretreated with other protease inhibitors
Authors: Schmidt, B Korn, K Moschik, B Paatz, C Uberla, K Walter, H
Citation: B. Schmidt et al., Low level of cross-resistance to amprenavir (141W94) in samples from patients pretreated with other protease inhibitors, ANTIM AG CH, 44(11), 2000, pp. 3213-3216
Evidence for recombination of live, attenuated immunodeficiency virus vaccine with challenge virus to a more virulent strain
Authors: Gundlach, BR Lewis, MG Sopper, S Schnell, T Sodroski, J Stahl-Hennig, C Uberla, K
Citation: Br. Gundlach et al., Evidence for recombination of live, attenuated immunodeficiency virus vaccine with challenge virus to a more virulent strain, J VIROLOGY, 74(8), 2000, pp. 3537-3542
Antiretroviral therapy during primary immunodeficiency virus infection caninduce persistent suppression of virus load and protection from heterologous challenge in rhesus macaques
Authors: Rosenwirth, B ten Haaft, P Bogers, WMJM Nieuwenhuis, IG Niphuis, H Kuhn, EM Bischofberger, N Heeney, JL Uberla, K
Citation: B. Rosenwirth et al., Antiretroviral therapy during primary immunodeficiency virus infection caninduce persistent suppression of virus load and protection from heterologous challenge in rhesus macaques, J VIROLOGY, 74(4), 2000, pp. 1704-1711
Suppression of acute viremia by short-term postexposure prophylaxis of simian/human immunodeficiency virus SHIV-RT-infected monkeys with a novel reverse transcriptase inhibitor (GW420867) allows for development of potent antiviral immune responses resulting in efficient containment of infection
Authors: Mori, K Yasutomi, Y Sawada, S Villinger, F Sugama, K Rosenwith, B Heeney, JL Uberla, K Yamazaki, S Ansari, AA Rubsamen-Waigmann, H
Citation: K. Mori et al., Suppression of acute viremia by short-term postexposure prophylaxis of simian/human immunodeficiency virus SHIV-RT-infected monkeys with a novel reverse transcriptase inhibitor (GW420867) allows for development of potent antiviral immune responses resulting in efficient containment of infection, J VIROLOGY, 74(13), 2000, pp. 5747-5753
Rapid, phenotypic HIV-1 drug sensitivity assay for protease and reverse transcriptase inhibitors
Authors: Walter, H Schmidt, B Korn, K Vandamme, AM Harrer, T Uberla, K
Citation: H. Walter et al., Rapid, phenotypic HIV-1 drug sensitivity assay for protease and reverse transcriptase inhibitors, J CLIN VIRO, 13(1-2), 1999, pp. 71-80
An anti-HIV strategy combining chemotherapy and therapeutic vaccination
Authors: Rosenwirth, B Bogers, WMJM Nieuwenhuis, IG Ten Haaft, P Niphuis, H Kuhn, EM Bischofberger, N Erfle, V Sutter, G Berglund, P Liljestrom, P Uberla, K Heeney, JL
Citation: B. Rosenwirth et al., An anti-HIV strategy combining chemotherapy and therapeutic vaccination, J MED PRIM, 28(4-5), 1999, pp. 195-205
Design elements for a computerized patient record
Authors: Adelhard, K Holzel, D Uberla, K
Citation: K. Adelhard et al., Design elements for a computerized patient record, METH INF M, 38(3), 1999, pp. 187-193
Risultati: 1-15 |